Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trinity BiotechTRIB -9.02%38 Market Cap is $8.35 Mil as of Aug. 01, 2026. GuruFocus rates TRIB with a GF Score™ of 38/100 and a GF Value™ of $22.79 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 862 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 86.66% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Trinity Biotech's share price for the quarter that ended in Dec. 2025 was $23.73. Trinity Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 0.62 Mil. Therefore, Trinity Biotech's market cap for the quarter that ended in Dec. 2025 was $14.81 Mil.
Trinity Biotech's quarterly market cap
declined
from Dec. 2024 ($15.82 Mil) to Jun. 2025 ($12.11 Mil) but then
increased
from Jun. 2025 ($12.11 Mil) to Dec. 2025 ($14.81 Mil).
Trinity Biotech's annual market cap
declined
from Dec. 2023 ($16.47 Mil) to Dec. 2024 ($15.82 Mil) and
declined
from Dec. 2024 ($15.82 Mil) to Dec. 2025 ($14.81 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Trinity Biotech's Enterprise Value for Today is $140.67 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Trinity Biotech Market Cap Related Terms
Trinity Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Trinity Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a Market Cap of $8.35 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #747 out of 862 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is Trinity Biotech's Market Cap too high?
Trinity Biotech's current Market Cap is $8.35 Mil. The Medical Devices & Instruments industry median Market Cap is 113.83. Trinity Biotech's value of $8.35 Mil is 92.7% below this industry median. Based on the distribution chart, Trinity Biotech ranks #747 out of 862 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Market Cap compare to STME and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #747 out of 862 companies for Market Cap. This places Trinity Biotech in the lower half of its industry. The industry median Market Cap is 113.83. Trinity Biotech's value of $8.35 Mil is 92.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 113.83, based on 862 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current Market Cap of $8.35 Mil is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Market Cap is $8.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $22.79, compared to a current price of $12.37 — trading 45.7% below its estimated fair value. The current Market Cap is $8.35 Mil and 92.7% below the Medical Devices & Instruments industry median of 113.83. Trinity Biotech's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Market Cap is $8.35 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $12.37 is trading 45.7% below its estimated GF Value™ of $22.79.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Market Cap: $8.35 Mil
GF Value™: $22.79 vs. price of $12.37 (45.7% below fair value)
Industry Position: 92.7% below the Medical Devices & Instruments median (#747 of 862)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
38GF Score
Get the complete analysis for TRIB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
